MEF2C enhances dopaminergic neuron differentiation of human embryonic stem cells in a parkinsonian rat model.
Human embryonic stem cells (hESCs) can potentially differentiate into any cell type, including dopaminergic neurons to treat Parkinson's disease (PD), but hyperproliferation and tumor formation must be avoided. Accordingly, we use myocyte enhancer factor 2C (MEF2C) as a neurogenic and anti-apop...
Guardado en:
Autores principales: | Eun-Gyung Cho, Jeffrey D Zaremba, Scott R McKercher, Maria Talantova, Shichun Tu, Eliezer Masliah, Shing Fai Chan, Nobuki Nakanishi, Alexey Terskikh, Stuart A Lipton |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/53ba5c9a0de04197981d40a27e5ed34c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism
por: Shichun Tu, et al.
Publicado: (2017) -
Dopaminergic Modulation of Spectral and Spatial Characteristics of Parkinsonian Subthalamic Nucleus Beta Bursts
por: Matthias Sure, et al.
Publicado: (2021) -
Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses.
por: Junqiang Yan, et al.
Publicado: (2011) -
Predicted transmembrane proteins with homology to Mef(A) are not responsible for complementing mef(A) deletion in the mef(A)–msr(D) macrolide efflux system in Streptococcus pneumoniae
por: Valeria Fox, et al.
Publicado: (2021) -
Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.
por: Judith A Potashkin, et al.
Publicado: (2012)